Tiotropium for Asthma

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of Saskatchewan

Prior Safety Data

Trial Summary

What is the purpose of this trial?Evaluate single dose (2 x 2.5mcg/puff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.

Eligibility Criteria

This trial is for individuals with asthma. Participants should be able to perform lung function tests and must not have had a respiratory infection or asthma exacerbation within the last four weeks. They cannot take part if they are currently smokers, have other significant health issues, or are using certain medications that might interfere with the study.

Inclusion Criteria

My asthma hasn't worsened or needed more treatment due to allergies in the last 4 weeks.

I am 18 years old or older.

I am not pregnant or breastfeeding.

Exclusion Criteria

I have smoked more than 10 packs of cigarettes a year.

Participant Groups

The trial is testing Tiotropium (Spiriva®), an inhaled medication, against a placebo. Each participant will receive a single dose of either Tiotropium or placebo before being exposed to an allergen to see how it affects their early asthmatic response by measuring changes in lung function.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Tiotropium treatmentExperimental Treatment1 Intervention

2 puffs tiotropium

Group II: PlaceboPlacebo Group1 Intervention

2 puffs placebo